[1] Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol,2019,4:135-184.
[2] WHO, UNICEF. Estimates of national immunization coverage. Geneva: World Health Organization, 2014. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragehepb_bd.html.
[3] Liang X,Bi S,Yang W,et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine,2009,29:6550-6557.
[4] Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med, 2016, 374: 2324-2334.
[5] Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med,2018, 378: 911-923.
[6] Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis, 2016,16: 1399-1408.
[7] Polaris Observatory Collaborators. Global prevalence, treat-ment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol,2018,3:383-403. |
